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 I 
Preface 
The purpose of this thesis was to investigate the prognostic and economic aspects of 
molecular-genetic assays in breast cancer and gather the newest research literature on this 
topic, and I conducted a systematic literature search to gather an overview on the latest 
research on this field.  
The fields of medical oncology and pathology has been an interest of mine since I started 
studying medicine, and I have always been interested in scientific research. I therefor applied 
for the integrated research program for medical students October 2016 and got accepted in 
May 2017. I joined the Translational Cancer Research Group at the Department of Medical 
Biology at the University of Tromsø and started my PhD-project on the Norwegian Women 
and Cancer Study Cohort, researching immunological markers in invasive breast cancer. 
Through working with my PhD-project I had a growing interest in the genetic aspects of 
breast cancer.  
The project required no extra funding or REK-approval. The literature search and all writing 
were conducted solely by me. I want to thank my supervisors, postdoc Line Leonore Haugan 
Moi and professor Lill-Tove Rasmussen Busund, who had the idea for the thesis and have 
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Background: Breast cancer is the most commonly diagnosed cancer in women 
internationally, and the most common cause of cancer related death among women. There are 
many ways to classify breast cancer, and breast cancer can be divided into several subgroups 
depending on which classification system is used. Pathological reports of breast carcinoma 
not only depend on one of these systems but include histopathological classification, grade of 
the tumor, and immunohistochemical (IHC) parameters like estrogen receptor (ER), 
progesterone receptor (PR), HER2- and Ki67-status. With the development of microarrays, it 
is now possible to analyze the genes of the cells, and with gene expression profiling (GEP) we 
have been able to evaluate breast cancer prognosis based on the gene expression of the cancer 
cells. Different genetic signatures of breast cancer have been obtained through DNA 
microarray technology, RNA sequencing and bioinformatic models. Some of these signatures 
have been validated through clinical studies and been translated into commercial prognostic 
assays. Four such commercial prognostic assays are Oncotype DX, MammaPrint, 
EndoPredict and PAM5-ROR. 
Methods: A literature search were conducted on the databases Medline and Embase. The 
inclusion criteria of the search were based on the Population, Intervention, Comparison and 
Outcome (PICO) framework. The search included terms to identify studies assessing the 
prognostic or economic aspects of Oncotype DX, MammaPrint, EndoPredict or Prosigna. Out 
of a total of 290 identified studies, 5 were included in this thesis. 
Results: Through the systematic literature search only studies focusing on Oncotype DX were 
included. The litterateur search disclosed that the Oncotype DX recurrence score (RS) is 
significantly associated with worse prognosis. The Oncotype DX RS were associated with 
both overall survival, disease free survival and local recurrence. The literature search also 
disclosed that Oncotype DX may be cost effective, especially in the high-risk RS group, were 
chemotherapy seemed to be clearly cost-effective because of the gain of additional quality-
adjusted life-years (QUALY) at a low cost.  
Conclusion: The findings of this thesis suggest that Oncotype DX have an independent 
prognostic significance and is significantly associated with survival and risk of recurrence and 
may be helpful to guide treatment. Studies also show that Oncotype DX may be a cost 
effective alternative when used to guide adjuvant chemotherapy treatment. 
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1.1 Breast cancer epidemiology 
Breast cancer is the most commonly diagnosed cancer in women, both in Norway and 
internationally, and the most common cause of cancer related death among women (1, 2). It 
makes up for 22 % of cancer cases among women in Norway, and in 2018 3568 women were 
diagnosed with breast cancer in Norway, compared to 1235 women in 1970 (3). The 
prevalence of breast cancer in Norway was 49 314 in 2018, an increase from 34 749 in 2008 
(4). Figure 1 demonstrates the trends in breast cancer incidence in Norway from 1980 to 2018 
by age groups. In the United States approximately 182 000 women are diagnosed with breast 
cancer each year, which makes up about 26 % of cancer in women in the US (1).  For women 
in the age group 50 to 74 years the incidence of breast cancer in the UK has increased from 
150/100000 to approximately 275/100000 from 1960 to 1990, while in Japan the increase has 
been from 30/100000 to 60/100000 in the same period of time (5). Since the early 90s the 
incidence of breast cancer in females has further increased by about 23 % in the UK (6).  
Of the 9.6 million registered cancer deaths worldwide in 2018, breast cancer stood for 2.09 
million deaths (7). Even though the survival rate of breast cancer is improving with a 5-year 
survival of 90.7 %, 594 people died from breast cancer in Norway in 2017, of which 586 were 
women (4). This accounted for 20.0 % of cancer-related deaths in women in Norway in 2017. 
In stage IV the 5-year survival is decreased to 29.2 % (4). The survival of breast cancer has 
increased over the last 40 years, from a total survival around 70 to 80 % in the early 80s to 
almost 91 % today (4). In summary, the mortality of breast cancer has decreased whereas the 
incidence has increased globally. Figure 2 shows relative survival up to 15 years after 
diagnosis by age, from 2014 to 2018. 
Hormonal factors have been established as key factors in the development of breast cancer 
through epidemiological studies of the disease. Many of the known risk factors for breast 
cancer increase the exposure to estrogens in breast tissue, like obesity, early menarche, late 
menopause, oral contraception, hormonal therapies and alcohol (5, 8, 9). 
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1.1.1 Possible causes for increasing incidence in breast cancer  
The increase in incidence can in part be attributed to breast cancer screening programs 
introduced in many countries over the last decades (10). The Norwegian Breast Cancer 
Screening Program started in 1995/96 and included women in the age group 50 to 69 years, 
and from 1996 to 2007 the screening program detected 67 % of all breast cancers which were 
diagnosed in this time period (11). An increasing number of women participating in the 
screening program will most likely lead to an increased incidence, since the screening 
program can detect tumors that otherwise would go undetected (10, 11). Another possible 
reason to the increased incidence is the western lifestyle, with high fat consumption, high 
consumption of alcohol and low physical activity, which are factors associated with increased 
risk of developing breast cancer. An example of this is the increase in incidence and mortality 
of breast cancer in Japan, which may be attributed to changes in eating habits to a more 
western diet with high fat content and low content of fiber (9). Also, in many western 
countries and Japan, women wait longer to get their first child and also get fewer children 
than before (9, 12, 13). Low parity is associated with increased risk of breast cancer, probably 
due to factors such as longer exposure to estrogen and less breastfeeding (5, 6, 8, 9, 14). 
Another explanation for the increased incidence of breast cancer is younger age at onset of 
puberty, and thereby earlier menarche and earlier breast development, which in part is caused 
by increased body mass index (BMI) among children and environmental factors (15-18). As 
for most types of cancer, one of the most important causes for the increase in breast cancer 
incidence is increasing age and an older population (10).  
1.2 Breast cancer classification 
Breast cancer comprises a group of diseases with specific clinical, histopathological and 
molecular properties. There are many ways to classify breast cancer, and breast cancer can be 
divided into several subgroups depending on which classification system is used. Pathological 
reports of breast carcinoma should not only depend on one of these systems, but should 
include histopathological classification and grade of the tumor, and immunohistochemical 
(IHC) parameters like estrogen receptor (ER), progesterone receptor (PR), human epidermal 
growth factor receptor 2 (HER2)- and Ki67-status (19). Together with clinical variables such 
as tumor staging, these factors are conventionally used as prognostic and predictive markers 
(20). More recently, new molecular approaches, named intrinsic subtype classification, have 
been tested. These approaches focus on the gene expression profiles of the cancer cells. These 
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molecular approaches are not yet used in routine clinical practice or in treatment guidance, 
but promising results on the prognostic and predictive importance of molecular subtyping are 
emerging. 
1.2.1 Histopathological classification 
The histopathological classification of breast carcinomas is based on the morphological 
features of the tumors, and is an essential component of the pathological reports of breast 
cancers (19). Breast carcinomas can broadly be classified into two main groups; invasive 
carcinoma and carcinoma in situ, where carcinoma in situ can further be divided into ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS can be further divided 
into other groups. Invasive breast carcinomas can also be divided into a number of subclasses, 
where invasive ductal carcinoma, now referred to as invasive carcinoma of no special type 
(NST), is by far the most common, accounting for about 70 to 80% of all invasive breast 
lesions (21). Invasive lobular carcinoma (ILC) is another type of invasive breast cancer, 
which accounts for 5 to 15 % of invasive breast cancers (22). WHO has made a 
histopathological classification system for breast tumors, which in its’ current version 
includes about 20 major tumor types and 18 minor subtypes (19).  
Since histopathological classification is solely based on the morphological appearance of the 
cancer cells, this classification system is unable to mirror the heterogeneity of breast cancer 
because different cells within the same group, and even tumor, has different biological and 
clinical profiles. Alone, histopathological classification has not sufficient prognostic and 
predictive implication (19).  
Histological tumor grading is a grading system that evaluates the degree of differentiation in 
the tumor tissue. Today histological grading is one of the best-established prognostic factors 
for breast cancer, and the Nottingham Grading system (NGS) is the grading system for breast 
cancer that is recommended by various professional international bodies, like WHO and the 
EU. NGS is based on the evaluation of the degree of tubular or gland formation, the degree of 
nuclear pleomorphism (variability in the size and shape of the nuclei), and the mitotic count. 
Combined with lymph node evaluation and the tumor size, together with the Kalmar 
Prognostic Index, they constitute the Nottingham Prognostic index (23).  
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In the NSG, based on the evaluation of the degree of tubular or gland formation, the degree of 
nuclear pleomorphism, and the mitotic count, each of these features is given a score of either 
one, two or three points, where 1 point is closest to normal and three points is the least 
normal. For example, when evaluating the degree of glandular/tubular formation, 1 point is 
given when >75 % of the tumor area is forming glandular/tubular structures, while 3 points 
are given when <10 % of the tumor area is forming these structures. Based on the overall 
score the tumor is graded into grade 1, 2 or 3, where grade 3 has the worst prognosis (24).  
1.2.1.1 Carcinoma in situ 
Ductal carcinoma in situ (DCIS) is a non-invasive intraductal epithelial proliferation that do 
not infiltrate the basal membrane, hence the term “in situ” (“in place”), and is often 
considered a pre-malignant lesion of the breast (22). The epithelial cells are characterized by 
cellular and nuclear atypia such as increase in nuclear-cytoplasmic ratio and hyperchromasia 
(an increase in chromatin content in the nuclei, and thereby increased staining capacity). 
Women with DCIS have an increased risk of local recurrence of DCIS after resection, and an 
increased risk of developing invasive breast cancer (25). Lobular carcinoma in situ (LCIS) 
describes an intralobular proliferation of epithelial cells that do not infiltrate the basal 
membrane. These cells are often small, uniform and loosely cohesive. There are rarely 
atypical changes like nuclear pleomorphism and/or necrosis like in DCIS (22). The lobular 
architecture is usually intact, and mitoses are rarely observed. Women with LCIS also have an 
increased risk of developing invasive breast cancer (26).   
1.2.1.2 Invasive carcinoma 
No special type (NST) is the most common form of breast cancer and constitutes about 55 % 
of the incidence of newly diagnosed breast cancer (22), and 80 % of all infiltrative breast 
cancers (25). NST consists of malignant ductal cells that have broken through the basal 
membrane and invaded the surrounding tissue and can develop both with and without 
previous DCIS. The morphology of NST is highly variable, and the tumor can be of varying 
size. The tumor often shows diffuse sheets of nests of cells and variable degrees of 
differentiation. Breast cancer that stems from the mammary ducts can also be divided into 
other different subclasses based on a wide range of criteria (22, 25). Tubular carcinoma is 
another rare subgroup of breast cancer that is well differentiated. This subgroup is 
characterized by proliferation of oval elongated tubules with an open lumen. This subgroup 
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usually has a good prognosis and rarely metastasizes. Invasive cribriform carcinoma is 
another rare subgroup of ductal cancer that is often associated with a good prognosis and is 
characterized morphologically by islands of uniform tumor cells. These cells present little 
morphological atypia and there is no clear invasion of surrounding tissue. Invasive cribriform 
carcinoma can in some cases be difficult to separate from DCIS, and immunohistochemical 
staining for myoepithelial cells is necessary. Mucinous carcinomas are tumors that typically 
consist of small clusters of uniform epithelial cells with mild atypia. These cells secrete 
mucus. Medullary carcinoma are tumors consisting of poorly differentiated cells with pushing 
borders. These tumors are associated with prominent lymphoid infiltration, and are associated 
with good prognosis. In addition to these subgroups there are numerous of very rare 
subgroups of ductal cancer, like invasive papillary and micropapillary carcinoma, apocrine 
carcinoma, neuroendocrine carcinoma and metaplastic carcinoma (22, 26).  
Invasive lobular carcinoma (ILC) represents 5 to 15 % of all invasive breast tumors. ILC is 
characterized by small, round, uniform and non-cohesive cells. There are usually only small 
amounts of cytoplasm. These cells usually infiltrate the stroma in a single-file matter. ILC 
usually affects older women than NST. ILC can be further divided into subgroups. The most 
common subgroup of ILC is called “classic type” and is characterized by small uniform cells 
singly distributed in the stroma, without glandular differentiation. Whether or not the 
prognosis of ILC is better or worse than NST is not yet determined (22, 26). These 
carcinomas usually present diffuse infiltration and are often found to be larger than first 
expected from mammographic imaging and clinical examination and have a tendency to be 
multifocal.  
1.2.2 Immunohistochemical classification 
Immunohistochemistry (IHC) is a method used in histopathological diagnostics where 
antibodies are used to mark and visualize specific molecules/antigens. In the case of breast 
cancer IHC is routinely used to test for specific receptors. Tissue is harvested and prepared 
through a process of formalin-fixation, paraffin embedding, sectioning of the tissue blocks, 
de-paraffinization and blocking of specific and non-specific sites to prevent false positive 
detection. The stains used can either be chromogenic or fluorescent, and the antigen-detection 
can be either direct, where the primary antibodies is conjugated to a chromogen or 
fluorophore, or indirect, where a secondary antibody conjugated to a reporter dye  is used (27, 
28).  
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Breast cancer tumor cells are routinely tested for expression of ER, PR and HER2 with IHC 
in the diagnostic process of breast cancer. Breast tumors are divided into subgroups based on 
their expression of these receptor proteins; (ER+, PR+) HER2+, which are tumors with either 
ER or PR positivity and HER2 positivity, (ER+, PR+) HER2-, which are tumors with either 
ER or PR positivity and HER2 negativity, ER-,PR-, HER2-, which are triple-negative tumors, 
and ER-, PR-, HER2+, which are tumors with ER and PR negativity and HER2 positivity 
(29).  
The receptor status of the breast cancer has important prognostic and predictive value. The 
subgroups have different prognosis, as hormone-receptor positive breast cancer tends to grow 
more slowly, and triple negative breast cancer tend to be more aggressive and spread faster. 
Further, receptor status also guides targeted treatment, and hormone-receptor positive breast 
cancer allows for more treatment options. ER-positive breast cancer can be treated with 
estrogen-receptor blocker or aromatase inhibitors (30, 31), while triple-negative breast cancer 
does not allow for targeted endocrine treatment.  
1.2.3 TNM classification 
Tumor Nodal Metastasis (TNM)is the most widely used system for classification of cancer in 
the world. The TNM-classification is based on the size of the tumor (T), the number of lymph 
nodes involved (N) and the presence of metastases or not (M). The system used to day is the 
TNM7-classification (32). Each of these main variables (T, N and M) is further divided into 
subgroups. T is divided into Tmi, T1, T2, T3 and T4 depending on the size of the main tumor, 
N is divided into Nx, N1, N2 and N3 depending on the number of lymph nodes that present 
with metastases, and M is divided into M0 and M1 depending on whether there are distant 
metastases or not (33). For example, a patient that presents with a primary tumor of 1.5 cm 
(T1c), has metastasis in 4 lymph nodes in the armpit (N2a), and has no sign of distant 
metastasis (M0), has a T1cN2aM0 breast cancer, corresponding to a stage IIIA cancer.  
1.2.4 Molecular classification 
The development of gene technology and microarrays has enabled  analyzes of  genes of the 
cells, and gene expression profiling (GEP) has made it possible to evaluate breast cancer 
prognosis based on gene expression of the cancer cells (20). In 2000 Perou et al. proposed the 
existence of four molecular-genetic subgroups of breast cancer through high profile molecular 
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profiling studies of tumor cells; luminal, basal-like, normal breast-like and HER2-enriched 
breast cancer. These groups were distinguished by differences in their gene expression pattern 
(34). In a follow-up study in 2001 by Sorlie et al. six intrinsic subgroups of breast cancer were 
identified (35). Today we classify breast cancer into the 4 intrinsic subgroups luminal A, 
luminal B, basal-like and HER2-positive. These subgroups have been shown to correspond 
well with the histopathological classification and receptor-expression measurements of breast 
cancer, with for example the luminal A usually being ER and PR positive and HER2 negative 
with a low Ki67, while the HER2-enriched subgroup usually is ER and PR negative and 
HER2 positive with a high Ki67 (36). Since Perou et al. published their work in 2000 there 
have been many gene-expression profiling studies on breast cancer, many of them targeted at 
gaining the ability to better identify patients who will, and will not, benefit from 
chemotherapy and endocrine therapy (37).  
 Recent studies have also shown epigenetic modifications, such as DNA methylation in cancer 
cells, and compared this to the gene expression to investigate the role of the methylation in 
the prognosis of the patient (38). Gene expression data appears to be superior to e.g. DNA-
methylation data for breast cancer subtype classification, but DNA-methylation models may 
provide addition candidate genes for complementing existing therapy. 
1.2.5 Breast cancer classification today 
Today, breast cancer patient management still rely on pathology assessment (histologic type, 
histologic grade and ER/PR/HER2-status) supplemented with a few validated assays testing 
for biomarkers, even though more clinically relevant intrinsic subtypes are being identified 
(20, 22). The usefulness of current methods for classification of breast cancer into the intrinsic 
molecular subtypes (luminal A, luminal B, HER2 and basal-like) were evaluated by a panel of 
breast cancer and gene expression profiling experts through the 2012 IMPACT task force. 
The panel concluded that the classification based on ER, PR, HER2 and Ki67 through IHC is 
not sufficient to modify systemic treatment decisions alone, but the panel still recommends 
using IHC for ER and HER2 for identification of clinically relevant subgroups of breast 
cancer as a part of the diagnostic and prognostic evaluation of the disease (39).  
There are several limitations with the clinicopathological classification system used today. 
Nodal status is one of the main deciding factors for using chemotherapy, and women with 
breast cancer, particularly women with hormone receptor positive, HER2-negative breast 
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cancer, is at risk of overtreatment. It is important to develop test that objectively stratify 
patients into risk category. This way treatment can be tailored based on the individual patient 
prognosis, and not on a standard treatment regimen based on the nodal status of the patient 
(40). 
1.3 Prognostic factors in breast cancer 
Prognostic factors estimate clinical outcome and risk of tumor relapse independent of 
treatment, and help making the decision of which patients are candidates for adjuvant 
treatment. Predictive factors estimate the likelihood of response to specific treatments, and 
help making the decision of which type of treatment the patient should be given (41, 42).  
There are a lot of different prognostic factors, but the prognostic value of each individual 
factor varies greatly. Age is observed to be an independent prognostic factor in most types of 
cancer, and in breast cancer younger age is considered to be unfavorable to the prognosis. 
Lower age at disease-onset is shown to correlate with higher TNM-stage, high grade tumors, 
hormone-receptor negativity and HER2-overexpression (43, 44).   
Tumor size is another important independent prognostic factor, and larger size of the tumor 
indicates worse prognosis. Tumors larger than 2 cm are considered intermediate/high-risk 
cancers, while patients with a tumor <1 cm are reported to have close to 100 % 5-year 
survival (45). Nodal status is considered to be the most important independent prognostic 
factor in breast cancer. Studies have found that local lymph node status is a significant 
predictor for tumor recurrence, distant metastasis and overall survival. Tumor grade is also 
used to determine the patient’s prognosis, and studies have shown that patients with grade 1 
tumors have significantly better survival than those with grade 2 and 3 lesions (41, 45).  
HER2 status has also been used to determine the patients’ prognosis, and studies have 
generally found that patients with overexpression of HER2 have a worse prognosis. Some 
studies have shown that patient with HER2 overexpression have twice the mortality rate of 
women without detectable HER2. ER and PR have also been associated with the patients’ 
prognosis, where high expression of especially ER is associated with a better prognosis (41, 
45-47). The fact that some studies have found a better response to hormonal therapy in ER+ 
patient with the presence of PR indicates a prognostic factor for PR expression as well (42). 
Measurement of Ki67, a cell proliferation marker, is widely used in many countries to 
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determine the prognosis of the breast cancer patient, but the use of this marker is 
controversial, and the results of studies of Ki67 are conflicting. Some studies though conclude 
that post-chemotherapy Ki67 is a strong predictor for clinical outcome for the patient (47). 
Some expert panels suggest that Ki67 can be used in combination with other established 
prognostic factors, while other expert panels are against the use of Ki67 (45).  
Today the most widely used prognostic markers are lymph node status, tumor size, tumor 
grade, and peritumoural lymphovascular invasion (41, 45, 46). These markers also have 
important predictive value together with hormone receptor status. Lymph node metastases, 
large tumor size, high tumor grade and infiltrative growth indicates poorer prognosis, and also 
indicates the need for more aggressive treatment with cytotoxic chemotherapy. For example, 
in Norway, all patients with lymph node stage 1 to 3 are candidates for systemic treatment 
with chemotherapeutic drugs. Also, the presence of hotspot Ki67 > 30 % in the tumor tissue 
provides basis for adjuvant chemotherapeutic treatment. Hormone receptor status also have an 
important predictive value. Today, endocrine treatment is the main treatment for ER- and PR-
positive breast cancer patients. ER-antagonists and aromatase inhibitors are the two main 
treatment options for ER-positive patients. Also, targeted therapy with the monoclonal 
antibody against HER2 has greatly increased the prognosis in HER2-positive breast cancer 
patients, and studies shows up to 50 % reduction in risk of relapse (48). 
1.4 Economics of breast cancer 
In 2018 approximately 360 billion Norwegian Kroner (NOK) were spent on health in 
Norway, approximately 10,18 % of the gross domestic product (GDP) (49), a rise from 342 
billion NOK in 2017 (50). The total yearly cost of cancer in the Norwegian society is around 
40 billion NOK, where 17,5 billion NOK goes to the health care sector and 18 billion comes 
from lost earnings from the patients. If one includes Years of Life Lost (YLL) the estimated 
economic burden of cancer in Norway is 100 billion NOK per year (51). The total health costs 
of breast cancer is estimated to be approximately 1,7 billion NOK, making it the second most 
expensive form of cancer in Norway, only exceeded by colorectal cancer which has a total 
health cost of around 2 billion NOK (52).  
In 2018 the European average expenditure on health, as well as the expenditure of UK, was 
9,6 % of GDP, while Germany used 11,3 % (53) and 17.1 % were used in the USA (49). The 
estimated total cost of cancer in the USA is estimated to be more than 180 billion United 
States Dollar (USD) and in 2010 the total cost of treating breast cancer was 16.5 billion USD 
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(54). The total estimated cost of cancer in the UK is estimated to be 18.3 billion Great British 
Pounds (GBP) (55).  
1.5 Molecular-genetic profiling 
As mentioned earlier it is possible to analyze the genes of cancer cells through GEP and been 
able to evaluate breast cancer prognosis based on their gene expression. Different genetic 
signatures of breast cancer have been obtained through DNA microarray technology, RNA 
sequencing and bioinformatic models. Some of these signatures have been validated through 
clinical studies and been translated into commercial prognostic assays. These tests can stratify 
patients into different risk categories based on their expression of specific gene signatures and 
can help guide treatment together with other clinco-pathological factors such as lymph-node 
status (56). Four such commercial prognostic assays are Oncotype DX, MammaPrint, 
EndoPredict and PAM50-ROR.  
1.5.1 MammaPrint 
The Amsterdam 70-gene profile is a prognostic gene signature identified by the Netherlands 
Cancer Institute. This gene signature was developed through analysis of 78 frozen, node- 
negative breast cancer tumors in women younger than 55 years. Through comparisons in this 
cohort, the research group ended up with 70 genes to predict clinical outcome. This 
prognostic profile has since then been validated in other studies, for example MINDACT 
(36), and is now available for commercial use as MammaPrint to predict the risk of distant 
metastasis in T1-2 N0-1, ER-positive/negative and HER2-positive/negative, and to select 
patients who would benefit from chemotherapy (57, 58). MammaPrint is a microarray 
prognostic score which measures the mRNA expression of the 70 genes included in the 
profile in frozen tissue and stratifies the patients’ score into a low-risk or a high-risk group 
(59). Patients with low genomic risk are unlikely to develop distant metastasis and are 
therefore unlikely to benefit from adjuvant chemotherapy, while high-risk groups most likely 
will benefit from adjuvant chemotherapy. This test requires either formalin-fixed paraffin-
embedded (FFPE) tissue for clinical purpose, or fresh specimens usually for research purpose. 
All the tests are analyzed in central laboratories in Netherlands and USA (60).  
 11 
1.5.2 Oncotype DX 
The 21-gene recurrence score is a gene-assay test commercially known as Oncotype DX. This 
test is a RT-PCR-based signature that measures 21 genes. It was developed through the 
evaluation of 250 genes which correlates to recurrence. Oncotype DX can be used on FFPE 
tissue samples and gives a score on a scale from 0 to 100, where <18 is defined as low risk, 
18-30 as intermediate risk and >30 as high risk of recurrence. The tissue has to be sent to a 
clinical reference laboratory of Genomic Health, Inc. in Redwood, California in USA, to be 
analyzed. Oncotype DX can be used to measure the risk of recurrence in women with node-
negative, hormone receptor positive breast cancer or with DCIS, and it can be used to identify 
who would benefit from chemotherapy and/or endocrine therapy. In women with breast 
cancer with intermediate or high risk of recurrence, the benefits of chemotherapy will likely 
outweigh the risks of side effects, and in women with high risk of recurrence DCIS the 
benefits of radiotherapy will likely outweigh the risks of side effects. The test has been 
validated in many studies, for example TAILORx, and is one of the most used prognostic 
gene-signature tests in clinical practice (36, 37, 57-59, 61-64). 
1.5.3 Prosigna 
PAM50-ROR (Prosigna) is a RT-PCR test used on FFPE tissue. It measures the risk of 
recurrence by using the 50-gene profile from PAM50 classifier, which was originally 
designed to be a tool to classify the intrinsic subgroups of breast cancer. The score is reported 
on a scale from 0 to 100, and the patients are divided into low, intermediate or high risk. This 
test is used to measure the probability of recurrence in hormone receptor positive, early-stage 
breast cancer patients with 0 to 3 positive nodes. PAM50-ROR has been validated in several 
studies (36, 37, 59). Prosigna can be used on FFPE-tissue, and is analyzed in specialized 
molecular pathology laboratories, and is used to guide treatment. These tests may be 
performed locally, given the laboratories have the right specialized equipment. The test 
measures the risk of recurrence from 5 to 10 years after being diagnosed with breast cancer in 
postmenopausal women, after 5 years of therapy. Node-negative cancers are classified as low 
(risk score 0-40), intermediate (41-60) and high-risk (61-100). Node-positive cancer are 
classified as low (0-40) or high (41-100) (65, 66). This test has shown to be prognostic for 
ER-positive, post-menopausal women treated with endocrine therapy alone, and to be both 
prognostic and predictive of endocrine therapy in pre-menopausal women treated with 
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adjuvant endocrine therapy. High risk patients have a higher risk of metastasis and may have 
more benefit for adjuvant treatment (67).  
1.5.4 EndoPredict 
EndoPredict is a RT-PCR-based assay that measures the RNA of 12 genes, 8 cancer genes 
and 3 housekeeping genes and 1 control gene. It is used to measure the risk of recurrence in 
estrogen receptor positive, HER2 receptor negative and node-negative breast cancer patient 
treated with adjuvant endocrine therapy alone. The prognostic value of EndoPredict has been 
validated in several studies. EndoPredict stratifies the patient score into two groups; a low risk 
and a high-risk group. This score is usually combined with other prognostic factors, such as 
tumor size and node-status, to compute a more comprehensive score, named EPclin (36, 37, 
59). This assay can be performed on FFPE-tissue, and can be analyzed in diagnostic 
molecular pathology laboratories that has established the EndoPredict assay in their routine 
diagnostics (68).  The EPclin score is used to predict the 10-year distant recurrence (DR) rate 
and is further used to guide treatment decision. High risk patients are more eligible for 
adjuvant chemotherapy (69). The EPclin Risk Score is given as a number between 1.1 and 
6.2, that indicates the risk of recurrence, and the score is separated in two one out of two 
groups; low-risk score and high-risk score. An EPclin score > 3.3287 indicates high risk of 
recurrence, > 10%. A score < 3.3287 indicates low risk of recurrence, < 10 %. The EPclin-
score is illustrated on a curve (70).  
1.6 Aims of the thesis  
In this literature review I have looked at the four prognostic gene-signature tests 
MammaPrint, Oncogene DX, PAM50-ROR and EndoPredict. Through the literature analysis 
I have looked at the advantages and the limitations of each of these tests, with focus on 2 
main aspects, and presented a brief overview:  
1. Prognostic information – What are the advantages of molecular-genetic prognostic 
tests in breast cancer for the individual patient and for the health-care providers? Do 
they provide any prognostic information outside of the standard classification of breast 
cancer? 
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2. Economics – Are there conducted any studies on the cost-effectiveness of the use of 
these gene-signature tests? Are the tests affordable, and can they be implemented in 
routine practice, or are they too expensive?  
2 Methods  
2.1 Data source and search strategy 
A systematic literature search was performed to assess the prognostic and economic aspects 
of molecular-genetic profiling of female breast cancer patients. To perform the literature 
search I followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA). The literature search was conducted May 13. 2020 in Medline and EMbase using 
the search engine Ovid. The search consisted of a combination of Medical Subject Headings 
(MeSH) terms and Emtree terms, and highly relevant terms from keywords, title and abstract. 
The search terms were allocated in three groups: 1. Breast cancer; 2. Molecular-genetic tests; 
3. Outcome. The different search terms within each group were combined with “OR”, and the 
categories were combined with “AND”. The reference list of the included articles from the 
literature search were also screened for relevant articles. Figure 3 shows the search terms 
included in this thesis.  
2.2 Selection criteria 
The inclusion criteria of this literature review were based on the PICOS-framework: (i) 
population: Human breast cancer patients; (ii) intervention: either of the molecular genetic 
tests: MammaPrint, Oncotype DX, Prosigna or EndoPredict; (iii) comparison: not relevant in 
this thesis; (iv) outcome: direct health care costs of the use, or the prognostic value, of at least 
one of the molecular genetic tests; (v) study design: costing studies or prognostic studies. 
Furthermore, the studies had to be human studies, be of English language, full-text and 
published from year 2016 to present to be included in the search.  
I excluded any studies with the following characteristics: studies involving male subjects, 
studies involving CIS and not invasive carcinoma, non-scientific studies, reviews, studies 
were there were no full-text article available, and studies with topics irrelevant to this thesis.  
2.3 Literature search and data extraction 
Through the literature search a total of 290 records were found, 136 in Medline and 154 in 
Embase. The records were exported to EndNote X9. Here further steps in the selection 
procedure were carried out. 35 duplicates were identified and removed, and 255 records were 
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screened in the title and abstract for eligibility. After screening the title and the abstracts, 221 
records were excluded due to not matching the inclusion criteria, or due to matching one or 
more of the exclusion criteria presented in this thesis. The 34 remaining articles were 
analyzed full text. After reviewing the articles, five articles were chosen as eligible based on 
the inclusion criteria and included in this thesis. The process of the literature search and data 
extraction is shown in figure 4. 
2.4 Data analysis 
Relevant data from the five selected articles included in the thesis were extracted from 
EndNote X9 to a Microsoft Excel spreadsheet. The excel spreadsheet included author name, 
journal name, study design, study population, results and conclusion. The results from the 
articles were divided in prognostic information and/or health costs information. Findings from 
the prognostic studies were considered significant if the corresponding 95% confidence 
intervals (CI) for their risk estimates (i.e. odds ratio (OR), hazard ratio (HR) or relative risk 
(RR)) did not include a point estimate of 1.00, and p-values were less than 0.05.  
2.5 GRADE 
The GRADE-guidelines (Grades of Recommendation, Assessment, Development and 
Evaluation) is a method created for appraising controlled studies and make recommendations 
for systematic reviews and guidelines. The method is used to assess the quality of evidence in 
controlled studies. This system classifies research articles into four different ranks; Very low, 
Low, Moderate and High, based on the study design, risk of bias and the size of the effect 
among other things (71). In this review I have evaluated the five articles from the literature 
search for quality of evidence, based on the GRADE-method. The GRADE-tables are listed in 
the end of this thesis.  
3 Results 
Five articles out of the 290 articles identified in the systematic literature search were included 
in this thesis. All of the articles were cohort studies, three retrospective cohort studies (72-74), 
one prospective cohort study (75), and one hypothetical cohort study/modeling study (76). All 
of the studies were prognostic studies except for the hypothetical cohort study which was an 
economic study. A complete list of all the studies included in this thesis, including their 
results, is shown in Table 1. The risk estimate and specific effect size of the prognostic studies 
is not mentioned in the text but is shown in Table 1. The risk estimates and effect size of the 
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economic study is discussed in the text. Through the systematic literature search only studies 
focusing on Oncotype DX were identified. No studies researching MammaPrint, EndoPredict 
or PAM50-ROR were included in the thesis due to either not fulfilling the inclusion criteria or 
having one or more exclusion criteria. Many of the studies involving MammaPrint, 
EndoPredict or PAM50-ROR first identified in the initial search were predictive studies, not 
prognostic studies. Many were also correlational studies, and not looking at specific 
endpoints.  
3.1 Oncotype DX 
All five of the articles selected from the systematic literature search studied Oncotype DX 
(72-76). All of the prognostic studies found that the Oncotype DX recurrence score (RS) were 
significantly associated with prognosis, although the studies had different endpoints. All of 
the studies found that high RS reduced the prognosis. The study by Turashvili et al. (72) 
found that the risk of locoregional recurrence (LRR) increased more than 4-fold in high RS 
patients compared to low RS patients. All of the prognostic studies evaluated ER-positive and 
HER2 negative breast cancer, except for Kizy et al.(73), where they studied the impact of 
Oncotype DX RS on ILC. Since ILC is mostly HER2-negative they only assume the patients 
are HER2-negative and did not include HER2 status in the analysis. Kizy et al. is also the 
only article that studies the impact of Oncotype DX RS on ILC, and found that a high-risk RS 
is independently associated with increased hazard of death when compared with low-risk RS. 
Turashvili et al. (72) was the only article that excluded lymph node-positive breast cancer, 
while the other articles either included pN0-1- or pN1 breast cancer. None of the articles 
included breast cancer with distant metastasis.  
One article conducted a risk-group specific cost-effectiveness analysis of adjuvant 
chemotherapy accounting for companion prognostic tests Oncotype DX and Adjuvant!Online 
(AO) (76). Here they applied a computer simulation model and conducted a hypothetical 
cohort study of 100000 50-year-old women diagnosed with ER- and/or PR-positive, HER2-
negative and lymph node-negative breast cancer. Their outcome of interest included quality-
adjusted-life years (QUALY) and number of life years (LY). They also measured incremental 
cost-effectiveness ratios (ICER; EUR/QUALY). The research group compared their results to 
a Canadian study conducted by Paulden et al. (77) in a cross-country comparison. They found 
that in the high-risk RS group, chemotherapy seemed to be clearly cost-effective because of 
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the gain of additional QUALY at a low cost and found an ICER less than 3500 
EUR/QUALY. Chemotherapy was also cost-effective in the RS-group and AO group.  
3.2 MammaPrint, Prosigna and EndoPredict 
None of the studies included in this systematic literature review studied MammaPrint, 
Prosigna or EndoPredict. Many of the articles in the initial search focused on these three 
molecular-genetic profiling tests, but these studies were excluded from the review due to 
being predictive studies, correlational studies or including male breast cancer. Many of the 
studies from the initial search investigated the prognostic value of the PAM50 intrinsic 
subgroups, but not the PAM50-ROR. For this reason, I am not able to evaluate the prognostic 
or economic aspects of MammaPrint, Prosigna or PAM50 in this thesis.  
4 Discussion 
In this systematic review, the goal was to evaluate the prognostic and economic impact of the 
four well known genomic profiles Oncotype DX, MammaPrint, Prosigna and EndoPredict. 
Only five studies focusing on Oncotype DX fulfilled the inclusion criteria and were included 
in this thesis. Four of these articles were prognostic studies, and all of them found that 
Oncotype DX RS is significantly associated with survival outcome in breast cancer, and the 
RS result provided an independent value in staging of breast cancer. All of the studies showed 
that a high RS is significantly associated with higher risk of LRR and mortality, while low RS 
is significantly associated with higher breast cancer-specific survival (BCSS), disease-free 
survival (DFS) and overall survival (OS).  
One article studied the cost effectiveness of the use of Oncotype DX and compared it with 
AO and found that in intermediate and high-risk RS-groups chemotherapy was effective and 
potentially cost effective. This is similar to the findings of Blok et al. (78). Blok et al 
conducted a systematic literature review on the clinical and economical value of gene the 
expression profiles Oncotype DX, MammaPrint, EndoPredict and Prosigna, and found that 
most evaluations estimated that genomic testing is cost-effective, with costs that are 
acceptable in relation to patient outcome.   
With regard to MammaPrint, EndoPredict and Prosigna, this systematic review found no 
studies eligible for inclusion. This is commonly known as “empty review”, and the issues of 
empty reviews was introduced to the literature by Lang et al. in 2007 (79), and proposed that 
the authors of empty reviews should note observations from ineligible studies that were 
 17 
found. This may be problematic, as noted by Green et al. (80), since conclusions based upon 
studies which do not meet inclusion criteria specified in the review protocol increases the risk 
of bias and may be misleading. Both Lang et al. and Green et al. outline the benefits and 
importance of publishing empty reviews as they tell us who is undertaking the reviews and 
thus who is interested in the topic. Further, they highlight major research gaps, indicate the 
current state of research evidence and they play an important role in highlighting areas 
requiring further research.   
4.1 Limitations 
This thesis has several limitations. First, even though the systematic literature search also 
included MammaPrint, Prosigna and Endopredict, only studies focusing on Oncotype DX 
were included in the thesis. There may be several reasons for this. First, the research question 
we propose may be too specific with overly strict methodological criteria. This secures more 
relevant articles and higher quality evidence but may result in many articles of interest not 
being included in the search. Also, MammaPrint, Prosigna and EndoPredict are relatively new 
tests compared to Oncotype DX, which have already been validated in many studies.  
Second, the definition of tumor subtypes varies across the included studies. All of the 
included studies evaluate the prognostic value of Oncotype DX RS in ER-positive breast 
cancer, but the TNM-classification and tumor grade vary across the studies. Also, the 
accepted clinicopathological definition elaborated by the St. Gallen International Breast 
Cancer Conference Expert Panel recommended implementing Ki67 to the subtype definition 
(81). Even though this thesis did not aim to evaluate the relation between the molecular-
genetic assays and Ki67, one of the included studies did evaluate the impact of RS on DFS 
within Ki67 subgroups and found a significant correlation. 
Third, this thesis only includes one economic study on the cost-effectiveness of Oncotype 
DX, performed in Austria. This study showed the cost-effectiveness of Oncotype DX in 
intermediate and high-risk RS groups, and the possible value of implementation of Oncotype 
DX in the decision making of possible adjuvant chemotherapy. These results are based on 
Austrian economy and health care system and is not directly transferable to other countries. 
However, their results were comparable to a Canadian study (77). 
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4.2 Implications 
In this thesis we have disclosed the prognostic and economic value of Oncotype DX in breast 
cancer. Given the high mortality in late-stage breast cancer and high morbidity associated 
with adjuvant chemotherapy, it is important to identify which patients are at high risk and 
which patients are at low risk of advanced disease. Oncotype DX may be able to assist in 
differentiating between high risk and low risk patients, and who will benefit from adjuvant 
treatment.  
5 Conclusion 
The findings of this thesis suggest that Oncotype DX have an independent prognostic 
significance and is significantly associated with survival and risk of recurrence and may be 
used to help guide treatment. Studies also show that Oncotype DX may be a cost effective 
alternative when used to guide adjuvant chemotherapy treatment. This thesis is in agreement 
with a growing amount of research suggesting that molecular genetic profiling tests have a 
distinct prognostic value. No information is available from the current systematic literature 
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